证券日报网讯 8月20日晚间，华润三九发布公告称，公司计划于2025年8月28日（星期四）15：00-16： 00联合公司控股子公司昆药集团股份有限公司、天士力医药集团股份有限公司举办2025年半年度业绩说 明会。 （编辑 任世碧） ...

证券日报网讯8月20日晚间，昆药集团（600422）发布公告称，公司计划于2025年8月28日15：00-16： 00联合公司控股股东华润三九（000999）医药股份有限公司、公司关联方天士力（600535）医药集团股 份有限公司举行2025年半年度网上业绩说明会。 ...

Group 1 - The company Tianjin Tasly Pharmaceutical Co., Ltd. announced plans to hold a semi-annual performance briefing on August 28, 2025, from 15:00 to 16:00 [2] - The briefing will be conducted in collaboration with its controlling shareholder, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., and its affiliate, Kunming Pharmaceutical Group Co., Ltd. [2]

关于控股子公司昆药集团担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 股票代码：000999 股票简称：华润三九 编号：2025—066 华润三九医药股份有限公司 一、担保情况概述 1. 担保事项履行的相关程序 为适应昆药集团及其相关下属公司业务发展需要，满足相关公司融资担保需求，经华润 三九董事会 2025 年第五次会议及 2024 年年度股东会审议通过，2025 年度昆药集团及其下 属子公司预计为昆药集团下属子公司不超过人民币 4.5615 亿元的银行融资授信业务提供连 带责任担保，详见《华润三九医药股份有限公司关于公司控股子公司昆药集团 2025 年度担 被担保人：华润三九（酉阳）制药有限公司（以下简称"酉阳制药"）。上述被担保人 为华润三九医药股份有限公司（以下简称"华润三九"）控股子公司昆药集团股份有限 公司（以下简称"昆药集团"）下属全资子公司，不存在关联担保。 本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为 1,000 万元，累计已实际为其提供的担保余额为 1,000 万元。 是否在 ...

股票代码：000999 股票简称：华润三九 编号：2025-065 华润三九医药股份有限公司 关于举行 2025 年半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 三、投资者参加方式 投资者可于 2025 年 8 月 28 日（星期四）下午 15:00-16:00，登录全景路演 （https://rs.p5w.net），参加本次 2025 年半年度业绩说明会。 欢迎广大投资者于 2025 年 8 月 21 日—2025 年 8 月 25 日 16:00 前访问全景投资者 （一） 会议召开时间： 2025 年 8 月 28 日下午 15:00-16:00 （二） 网络直播地址： 全景路演（https://rs.p5w.net） 关系互动平台（http://ir.p5w.net/zj/）进入问题征集专题页面，或通过公司邮箱 (000999@999.com.cn)进行提问。公司将在 2025 年半年度业绩说明会上对投资者普遍关 注的问题进行回答。 华润三九医药股份有限公司(以下简称"公司")已于 2025 年 8 月 16 日发布公司 202 ...

Core Viewpoint - China Resources Sanjiu's performance fell short of expectations in the first half of 2025, primarily due to a decrease in the incidence of respiratory diseases and adjustments in retail channels [1] Group 1: Financial Performance - The company's profit decline is significantly attributed to the completion of the Tian Shi Li acquisition, which increased the sales expense ratio due to the focus on hospital sales in Tian Shi Li's traditional Chinese medicine business [1] - The wholesale and retail business for pharmaceuticals and medical devices showed steady growth, achieving revenue of 1.74 billion yuan, a year-on-year increase of 3.3% [1] Group 2: Business Outlook - The pressure on the CHC (Consumer Health Care) business is considered temporary, with the company’s channel and brand advantages continuing to empower its business layout [1] - The company is expanding into cell therapy, metabolism, and oncology sectors [1] Group 3: Valuation - Based on the average price-to-earnings ratio of comparable companies, a valuation of 22 times PE for 2025 is suggested, corresponding to a target price of 45.10 yuan, maintaining a "buy" rating [1]

Investment Rating - The report maintains a "Buy" rating for the company [5][8]. Core Views - The company's performance has been under pressure due to a decrease in the incidence of respiratory diseases and adjustments in retail channels, resulting in a revenue growth of 5.0% year-on-year for the first half of 2025 [11]. - The integration of Tianshili has significantly boosted the prescription drug business, which saw a revenue increase of 100.2% year-on-year, while the self-medication (CHC) business faced a decline of 17.9% [11]. - The company is expanding its R&D pipeline with multiple collaborations in cell therapy, metabolism, and oncology, including partnerships for innovative drug development [11]. Financial Forecast and Investment Recommendations - The earnings per share (EPS) forecasts for 2025-2027 are adjusted to 2.05, 2.26, and 2.49 yuan respectively, down from previous estimates of 2.99, 3.39, and 3.93 yuan [5]. - The target price is set at 45.10 yuan based on a 22x PE valuation for 2025, reflecting a potential upside from the current price of 30.27 yuan [5][8]. - Revenue projections for 2025-2027 are 30.515 billion, 33.707 billion, and 37.163 billion yuan, with respective growth rates of 10.5%, 10.5%, and 10.3% [7]. Key Financial Metrics - The company reported a net profit of 2.853 billion yuan in 2023, with a projected increase to 4.152 billion yuan by 2027, reflecting a compound annual growth rate (CAGR) of approximately 10% [7]. - The gross margin is expected to stabilize around 52.5% in 2025, with net profit margins projected at 11.2% for the next few years [7]. - The company's price-to-earnings (P/E) ratio is forecasted to decrease from 17.7 in 2023 to 12.2 by 2027, indicating a potentially more attractive valuation over time [7].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 45.10 CNY, based on a 22x PE valuation for 2025 [5][8]. Core Insights - The company's performance has been under pressure due to a decrease in the incidence of respiratory diseases and adjustments in retail channels, resulting in a 5.0% year-on-year revenue growth to 14.81 billion CNY in the first half of 2025, while net profit attributable to the parent company decreased by 24.3% to 1.82 billion CNY [11]. - The prescription drug business saw significant growth, with revenues reaching 4.84 billion CNY, a 100.2% increase year-on-year, driven by the consolidation of Tian Shi Li [11]. - The company is expanding its R&D pipeline with multiple collaborations in cell therapy, metabolism, and oncology, including partnerships for innovative drug development [11]. Financial Summary - Revenue projections for 2025-2027 are 30.515 billion CNY, 33.707 billion CNY, and 37.163 billion CNY, respectively, with year-on-year growth rates of 10.5%, 10.5%, and 10.3% [7]. - The net profit attributable to the parent company is forecasted to be 3.422 billion CNY in 2025, with a growth rate of 1.6% [7]. - The company's gross margin is expected to stabilize around 52.5% in 2025, with a net margin of 11.2% [7].

Core Viewpoint - The company reported a decline in net profit and net profit excluding non-recurring items for the first half of 2025, primarily due to a high base effect from the previous year, while the prescription drug business showed strong growth [1][2]. Financial Performance - For 1H25, the company achieved revenue of 148.1 billion yuan, a year-on-year increase of 5.0%, but net profit attributable to shareholders decreased by 24.3% to 18.2 billion yuan, and net profit excluding non-recurring items fell by 26.5% to 17.0 billion yuan [1]. - In 2Q25, revenue increased by 16.8% year-on-year, while net profit attributable to shareholders and net profit excluding non-recurring items saw significant declines of 47.3% and 51.1%, respectively [1]. - Excluding the consolidation of Kunming Pharmaceutical Group and Tasly Pharmaceutical, the company's organic revenue and net profit for 1H25 decreased by 32.0% and 33.9% year-on-year, with 2Q25 showing declines of 22.1% and 61.5% [1]. Business Segments - The Consumer Health Care (CHC) segment faced pressure due to a decrease in demand, with 1H25 revenue of 79.9 billion yuan, down 17.9% year-on-year, attributed to lower cold incidence rates. However, growth is expected to resume in the second half of the year as the cold medicine delivery season approaches [2]. - The prescription drug business emerged as a growth driver, with 1H25 revenue reaching 48.4 billion yuan, a 100% year-on-year increase, driven by strong performance in existing businesses and the consolidation of Tasly [2]. Innovation and R&D - The company continues to focus on innovative drug development, with R&D expenses of 4.6 billion yuan, up 40.6%. During the reporting period, it obtained 8 drug registration certificates and has 205 projects under research, covering various fields including cardiovascular, metabolic diseases, and oncology [3]. - A notable collaboration with Ai Er Pu on the HiCM-188 project aims to advance clinical trials for a groundbreaking heart failure treatment, which has received clinical approval in both China and the U.S. [3]. Mergers and Acquisitions - The acquisition of a 28% stake in Tasly, completed in March 2025, has strengthened the prescription drug business, with both companies benefiting from complementary strengths in innovation, manufacturing, and marketing [4]. - Kunming Pharmaceutical Group is undergoing a transformation focused on its "777" brand and "Kun Chinese Medicine 1381" strategy, with expectations of revenue recovery as channel reforms progress [4]. Investment Outlook - The company is positioned for long-term growth through its CHC business stabilization, prescription drug innovation, and strategic mergers and acquisitions. Short-term performance is impacted by high base effects and channel integration challenges, leading to adjusted profit expectations for 2025-2027 [4].

Investment Rating - The report maintains a "Recommendation" rating for China Resources Sanjiu (000999) with a target price of 36.4 CNY [2][7]. Core Views - The company experienced revenue growth of 5.0% year-on-year in 1H25, but net profit attributable to shareholders decreased by 24.3% and net profit excluding non-recurring items fell by 26.5% due to a high base effect from the previous year [2][7]. - The report highlights that the CHC (Consumer Health Care) business faced pressure due to a decline in demand, while the prescription drug business showed robust growth, driven by the integration of Tian Shi Li and the performance of existing products [7]. - The company is focusing on innovation in drug development, with significant investments in R&D and multiple projects in various therapeutic areas [7]. Financial Summary - Total revenue is projected to grow from 27,617 million CNY in 2024 to 36,889 million CNY in 2027, with a compound annual growth rate (CAGR) of approximately 10.3% [2][8]. - Net profit attributable to shareholders is expected to increase from 3,368 million CNY in 2024 to 4,477 million CNY in 2027, reflecting a CAGR of 15.2% [2][8]. - The report anticipates earnings per share (EPS) to rise from 2.02 CNY in 2024 to 2.68 CNY in 2027 [2][8]. Business Segments - The CHC business reported a revenue of 79.9 billion CNY in 1H25, down 17.9% year-on-year, primarily due to lower cold incidence rates [7]. - The prescription drug segment achieved a revenue of 48.4 billion CNY in 1H25, marking a 100% year-on-year increase, benefiting from the integration of Tian Shi Li and strong performance in existing products [7]. - The company is actively pursuing innovation in drug development, with 205 projects under research and development, and has received 8 drug registration certificates during the reporting period [7].